BioCentury
ARTICLE | Clinical News

AbbVie's elagolix meets in second Phase III for uterine fibroids

March 13, 2018 6:08 PM UTC

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-II (M12-817) trial, the second of two replicate Phase III trials of the candidate to treat uterine fibroids. AbbVie said a commercial launch of elagolix to treat uterine fibroids is planned for 2020, but the company declined to disclose a timeline for regulatory submissions.

In February, AbbVie said elagolix met the primary and all ranked secondary endpoints in the first trial, ELARIS UF-I (M12-815) (see BioCentury Extra, Feb. 21)...

BCIQ Target Profiles

GnRH/LHRH receptor